Emergent BioSolutions Files 8-K
Ticker: EBS · Form: 8-K · Filed: Sep 5, 2025 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $30.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Emergent BioSolutions filed an 8-K on 9/5 for an event on 9/2. Details TBD.
AI Summary
Emergent BioSolutions Inc. filed an 8-K on September 5, 2025, reporting an event on September 2, 2025. The filing is a current report under the Securities Exchange Act of 1934, with no specific details on the nature of the event provided in the excerpt.
Why It Matters
This filing indicates a material event has occurred for Emergent BioSolutions, requiring disclosure to investors and the public.
Risk Assessment
Risk Level: low — The filing is a standard 8-K current report without immediate disclosed negative or positive financial implications.
Key Numbers
- 001-33137 — SEC File Number (Identifies the company's filing history with the SEC.)
- 14-1902018 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- September 2, 2025 (date) — Earliest event reported
- September 5, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Gaithersburg, Maryland (location) — Principal executive offices
FAQ
What specific event triggered this 8-K filing for Emergent BioSolutions?
The provided excerpt does not specify the nature of the event reported on September 2, 2025, only that an 8-K was filed on September 5, 2025.
What is the primary purpose of an 8-K filing?
An 8-K filing is used by publicly traded companies to disclose material events that occur between the regular reporting periods.
Where are Emergent BioSolutions' principal executive offices located?
The principal executive offices are located at 300 Professional Drive, Gaithersburg, Maryland 20879.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Emergent BioSolutions' fiscal year end?
Emergent BioSolutions' fiscal year ends on December 31.
Filing Stats: 621 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-09-05 17:23:20
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
- $30.0 million — previously known as "AV7909") valued at $30.0 million. This modification relates to Emergent'
Filing Documents
- ebs-20250902.htm (8-K) — 29KB
- cyfendusmod.htm (EX-10.1) — 9KB
- a09022025cyfenduspressrele.htm (EX-99.1) — 16KB
- cyfendusmod001.jpg (GRAPHIC) — 253KB
- cyfendusmod002.jpg (GRAPHIC) — 85KB
- cyfendusmod003.jpg (GRAPHIC) — 173KB
- cyfendusmod004.jpg (GRAPHIC) — 66KB
- image2a.jpg (GRAPHIC) — 7KB
- 0001367644-25-000183.txt ( ) — 1015KB
- ebs-20250902.xsd (EX-101.SCH) — 2KB
- ebs-20250902_def.xml (EX-101.DEF) — 15KB
- ebs-20250902_lab.xml (EX-101.LAB) — 26KB
- ebs-20250902_pre.xml (EX-101.PRE) — 16KB
- ebs-20250902_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On August 29, 2025, Emergent BioSolutions Inc. ("Emergent") received a contract modification ("Modification No. 20") of the BARDA AV7909 Contract (as defined below) from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) (previously known as "AV7909") valued at $30.0 million. This modification relates to Emergent's AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority ("BARDA"), which became effective on September 30, 2016 (the "BARDA AV7909 Contract") and has been modified from time to time. The preceding description of Modification No. 20 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No. 20. Modification No. 20, with relevant redactions to protect confidential and sensitive information, is filed herewith as Exhibit 10.1 and is incorporated herein by reference. The BARDA AV7909 Contract is filed as a material agreement of Emergent as Exhibit 10.57 with Emergent's Annual Report on Form 10-K for the fiscal year ended December 31, 2024. On September 2, 2025, Emergent issued a press release announcing the contract modification. A copy of the press release is furnished as Exhibit 99.1 to this Current Report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Modification No. 20, effective August 29, 2025 to the BARDA AV7909 Contract. 99.1 Press release issued by Emergent BioSolutions Inc. on September 2 , 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: September 5, 2025 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer